Ouster to Supply Lidar Sensors for Komatsu's Suite of Autonomous Offerings
SAN FRANCISCO--(BUSINESS WIRE)-- Ouster, Inc. (Nasdaq: OUST) ('Ouster' or the 'Company'), a global provider of high-performance lidar sensors and software solutions, and Komatsu, a leading manufacturer of construction, mining, forestry and industrial heavy equipment, announced today that Ouster will be the lidar supplier for Komatsu's suite of autonomous mining equipment offerings. The two companies signed a multimillion-dollar agreement to equip Komatsu's equipment with advanced 3D digital lidar sensors. Ouster sensors include benefits such as zone monitoring and routine firmware updates that continuously improve the performance of the stack and accelerate product development.
Komatsu's autonomous offerings help customers worldwide increase productivity and reduce total cost of ownership while promoting zero harm. Advanced access to Ouster's future products for testing and development provides Komatsu with a strategic partnership, enabling the introduction of equipment with advanced functionality that creates value for customers.
The deal provides a pathway to an upgraded autonomy stack to replace legacy 2D lidar systems with 3D lidar for maximum perception and enhanced vehicle functionality. Komatsu's autonomous solutions will incorporate a mix of long and short-range OS sensors from Ouster's REV7 series to benefit future offerings to provide increased capabilities and intelligence, including improved detection, navigation, and collision avoidance.
'Ouster's products developed through this partnership can withstand the shock, vibration and temperature constraints while delivering the enhanced range and spatial awareness necessary to operate in harsh mining environments,' said Matt Reiland, Technical Director, Automation Innovation at Komatsu.
This agreement marks a significant milestone in Komatsu's ongoing journey to advance mining automation and safety. By integrating Ouster's cutting-edge lidar technology into mining equipment, Komatsu reaffirms its commitment to empower customers to operate more efficiently, safely, and sustainably.
About Komatsu
Komatsu develops and supplies technologies, equipment and services for the construction, mining, forklift, industrial and forestry markets. For more than a century, the company has been creating value for its customers through manufacturing and technology innovation, partnering with others to empower a sustainable future where people, business and the planet thrive together. Front-line industries worldwide use Komatsu solutions to develop modern infrastructure, extract fundamental minerals, manage forests, and create consumer products. The company's global service and distributor networks support customer operations to help enhance safety and promote productivity while working to optimize performance. Learn more at www.komatsu.com.
About Ouster
Ouster (Nasdaq: OUST) is a leading global provider of high-resolution lidar sensors and software solutions for the automotive, industrial, robotics, and smart infrastructure industries. Ouster is on a mission to build a safer and more sustainable future by offering affordable, high-performance sensors that drive mass adoption across a wide variety of applications. Ouster is headquartered in San Francisco, CA with offices in the Americas, Europe, and Asia-Pacific. For more information about our products, visit www.ouster.com, contact our sales team, or connect with us on X or LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Ouster intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current plans, estimates and expectations of management that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as 'expect,' 'will', 'may,' 'anticipate,' 'intend,' 'should,' 'plan,' 'can,' 'could,' 'offer,' 'estimate,' 'possible,' 'potential,' 'pursue,' 'demonstrate,' and the negative of these terms and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All statements, other than historical facts, including statements regarding the capabilities and benefits of Ouster's hardware offerings and software-attached offerings, including with respect to the enhancement of or inclusion of new features for mining automation, productivity and safety, all constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including, but not limited to, the possibility of cancellation or postponement of contracts or unsuccessful implementations; risks related to the adoption of its products and the growth of the lidar market generally; Ouster's ability to accurately anticipate market demand for its products and offerings; Ouster's ability to respond to evolving regulations and standards; and other important risk factors discussed in Ouster's Annual Report on Form 10-K for the year ended December 31, 2024, as may be further updated from time to time in Ouster's other filings with the SEC. Readers are urged to consider these factors carefully and in the totality of the circumstances when evaluating these forward-looking statements, and not to place undue reliance on any of them. Any such forward-looking statements represent management's reasonable estimates and beliefs as of the date of this press release. While Ouster may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, other than as may be required by law, even if subsequent events cause its views to change.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Walgreens (NASDAQ:WBA) Exceeds Q2 Expectations
Pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 7.2% year on year to $38.99 billion. Its non-GAAP profit of $0.38 per share was 11.3% above analysts' consensus estimates. Is now the time to buy Walgreens? Find out in our full research report. "On March 6, 2025, WBA entered into a definitive agreement to be acquired by entities affiliated with Sycamore Partners. The merger is currently expected to close in the third or fourth quarter of calendar year 2025, pending shareholder and regulatory approvals and other conditions to closing. Upon completion of the transaction, WBA common stock will no longer be listed on the Nasdaq Stock Market, and WBA will become a private company." Revenue: $38.99 billion vs analyst estimates of $36.59 billion (7.2% year-on-year growth, 6.5% beat) Adjusted EPS: $0.38 vs analyst estimates of $0.34 (11.3% beat) Operating Margin: 0.1%, in line with the same quarter last year Free Cash Flow Margin: 0.9%, similar to the same quarter last year Market Capitalization: $9.78 billion Primarily offering prescription medicine, health, and beauty products, Walgreens Boots Alliance (NASDAQ:WBA) is a pharmacy chain formed through the 2014 major merger of American company Walgreens and European company Alliance Boots. A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. With $154.6 billion in revenue over the past 12 months, Walgreens is a behemoth in the consumer retail sector and benefits from economies of scale, giving it an edge in distribution. This also enables it to gain more leverage on its fixed costs than smaller competitors and the flexibility to offer lower prices. However, its scale is a double-edged sword because it's harder to find incremental growth when you've penetrated most of the market. To expand meaningfully, Walgreens likely needs to tweak its prices or enter new markets. As you can see below, Walgreens grew its sales at a sluggish 3.8% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts). This shows it failed to generate demand in any major way and is a rough starting point for our analysis. This quarter, Walgreens reported year-on-year revenue growth of 7.2%, and its $38.99 billion of revenue exceeded Wall Street's estimates by 6.5%. Looking ahead, sell-side analysts expect revenue to decline by 1.6% over the next 12 months, a deceleration versus the last six years. This projection is underwhelming and indicates its products will see some demand headwinds. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Same-store sales is a key performance indicator used to measure organic growth at brick-and-mortar shops for at least a year. Walgreens has been one of the most successful retailers over the last two years thanks to skyrocketing demand within its existing locations. On average, the company has posted exceptional year-on-year same-store sales growth of 6.7%. Note that Walgreens reports its same-store sales intermittently, so some data points are missing in the chart below. We were impressed by how significantly Walgreens blew past analysts' revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. No guidance was provided due to the impending acquisition of the company. Zooming out, we think this was a solid quarter. The stock remained flat at $11.40 immediately after reporting. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
20 minutes ago
- USA Today
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value Jaguar Health, Inc. ( NASDAQ:JAGX ) ('Jaguar' or 'the Company'), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset. 'Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation,' said Lisa Conte, Jaguar's Founder and CEO. 'Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company.' Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for Canalevia® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. CONTACT: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc. View the original press release on ACCESS Newswire
Yahoo
20 minutes ago
- Yahoo
AI Platform Vermillio Named to TIME100 Most Influential Companies List
CHICAGO, June 26, 2025--(BUSINESS WIRE)--Vermillio, the AI licensing and protection platform, today was named to the annual TIME100 Most Influential Companies list, highlighting 100 companies making an extraordinary impact around the world. Vermillio was recognized for empowering humanity to thrive in the Al era through its groundbreaking TraceIDTM technology, which both provides comprehensive detection and removal capabilities for unauthorized AI-generated material and enables IP holders to protect and monetize their content. Vermillio earned a spot on the prestigious list for helping "protect (and potentially license) name, image, and likeness (NIL) data." The distinction follows Co-Founder and CEO Dan Neely's inclusion in TIME's 2024 TIME100 Most Influential People in AI, underscoring the company's continued leadership in the ever-changing AI space. Providing cutting-edge protection and third-party attribution, Vermillio's TraceID enables individuals and IP holders to take advantage of the benefits of AI with secure control of their data and AI rights. TraceID offers the ability to manage terms, conditions, and usage rights while capitalizing on new revenue streams made possible with AI. The Vermillio team designed TraceID to eliminate key concerns around consent, credit, and compensation with Generative AI. TraceID's extensive offerings include IP and NIL content monitoring and reporting, alerts and takedowns, lost revenue management, IP and NIL asset preparation for AI licensing, auditing of authorized AI licenses, and payment management. Vermillio's Dan Neely is also advancing major conversations about AI around the world. He has provided instrumental guidance for landmark legislation in both the United States, including the TAKE IT DOWN ACT, and the United Kingdom. "As we continue to see courts dismantling copyright protections, major AI platforms fail to prioritize the rights of creators, and everyday people fall victim to deepfake abuses, artists, IP holders, and individuals need tools to protect themselves," said Dan Neely, Co-Founder & CEO of Vermillio. "We designed Vermillio to fill these gaps and take care of people when the system won't. We're thrilled to be recognized by TIME for our work so far and look forward to continuing to push for a future where we are all empowered, not exploited, by AI." As part of its mission to empower humanity in the era of AI, Vermillio continues to partner with leading talent, studios, record labels, and more, especially through a unique TraceID partnership with Sony Music Entertainment, which recently led Vermillio's $16 million Series A funding round. To demonstrate the unique opportunity that authenticated AI with TraceID presents to artists and labels Vermillio and Sony Music collaborated with The Orb and David Gilmour of Pink Floyd to develop an AI music experience where fans "remixed" their tracks with the artists' original music – all powered by the seamless and secure control of TraceID. Last year, Vermillio announced a first-of-its-kind partnership with talent agency WME to shield their clients from IP theft and deliver opportunities to monetize their name, image and likeness (NIL) by securely licensing their data. The company also recently announced partnership with legendary entertainer, author, and philanthropist Steve Harvey to proactively protect his fans against the unauthorized use of his image. See the full fifth-annual TIME100 Most Influential Companies here: About VermillioVermillio is an AI licensing and protection platform with a mission to empower humanity to thrive in the era of Generative AI. Providing cutting-edge protection and control, Vermillio's TraceIDTM enables talent and IP holders to take advantage of the benefits of Generative AI in a safe and secure environment while understanding where their valuable data is being used. The company is building the guardrails for a Generative AI internet to enable talent, studios, record labels, and more to protect and monetize their content. Co-founded by Dan Neely, who recently made TIME's list of 100 most influential individuals in AI, Vermillio's team is led by experienced technologists who bring significant collective experience building AI software and scaled transaction systems. Learn more at View source version on Contacts Media Contact: Sarah Rothman | Vermillio@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
